139 related articles for article (PubMed ID: 21463123)
1. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens.
Noel P
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():62-4. PubMed ID: 21463123
[TBL] [Abstract][Full Text] [Related]
2. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical demonstration of acid phosphatase isoenzyme 5 (tartrate-resistant) in paraffin sections of hairy cell leukemia and other hematologic disorders.
Hoyer JD; Li CY; Yam LT; Hanson CA; Kurtin PJ
Am J Clin Pathol; 1997 Sep; 108(3):308-15. PubMed ID: 9291460
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease, its detection and significance in hairy-cell leukemia.
Zák P; Chrobák L; Dĕdic K
Acta Medica (Hradec Kralove); 1999; 42(3):85-8. PubMed ID: 10677893
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
6. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.
Mhawech-Fauceglia P; Oberholzer M; Aschenafi S; Baur A; Kurrer M; Von Rohr A; Hsu-Schmitz SF; Wagner B; Delacretaz F; Hurwitz N;
Arch Pathol Lab Med; 2006 Mar; 130(3):374-7. PubMed ID: 16519567
[TBL] [Abstract][Full Text] [Related]
7. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
9. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
Tallman MS
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():65-8. PubMed ID: 21463116
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Wheaton S; Tallman MS; Hakimian D; Peterson L
Blood; 1996 Feb; 87(4):1556-60. PubMed ID: 8608247
[TBL] [Abstract][Full Text] [Related]
12. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
13. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia.
Ellison DJ; Sharpe RW; Robbins BA; Spinosa JC; Leopard JD; Saven A; Piro LD
Blood; 1994 Dec; 84(12):4310-5. PubMed ID: 7994047
[TBL] [Abstract][Full Text] [Related]
14. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia.
Hakimian D; Tallman MS; Kiley C; Peterson L
Blood; 1993 Sep; 82(6):1798-802. PubMed ID: 7691237
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of Dual Immunohistochemistry Staining in Detection of Hairy Cell Leukemia in Bone Marrow.
Gupta GK; Sun X; Yuan CM; Stetler-Stevenson M; Kreitman RJ; Maric I
Am J Clin Pathol; 2020 Feb; 153(3):322-327. PubMed ID: 31665200
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow and splenic histology in hairy cell leukaemia.
Wotherspoon A; Attygalle A; Mendes LS
Best Pract Res Clin Haematol; 2015 Dec; 28(4):200-7. PubMed ID: 26614898
[TBL] [Abstract][Full Text] [Related]
17. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study.
Matutes E; Meeus P; McLennan K; Catovsky D
Br J Haematol; 1997 Aug; 98(2):375-83. PubMed ID: 9266936
[TBL] [Abstract][Full Text] [Related]
18. An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia.
Sherman MJ; Hanson CA; Hoyer JD
Am J Clin Pathol; 2011 Sep; 136(3):390-9. PubMed ID: 21846914
[TBL] [Abstract][Full Text] [Related]
19. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
Ravandi F; Kreitman RJ; Tiacci E; Andritsos L; Banerji V; Barrientos JC; Bhat SA; Blachly JS; Broccoli A; Call T; Chihara D; Dearden C; Demeter J; Dietrich S; Else M; Epperla N; Falini B; Forconi F; Gladstone DE; Gozzetti A; Iyengar S; Johnston JB; Jorgensen J; Juliusson G; Lauria F; Lozanski G; Parikh SA; Park JH; Polliack A; Quest G; Robak T; Rogers KA; Saven A; Seymour JF; Tadmor T; Tallman MS; Tam CS; Thompson PA; Troussard X; Zent CS; Zenz T; Zinzani PL; Wörmann B; Rai K; Grever M
Blood Cancer J; 2022 Dec; 12(12):165. PubMed ID: 36509740
[TBL] [Abstract][Full Text] [Related]
20. Hairy cell leukemia: early immunophenotypical detection and quantitative analysis by flow cytometry.
Babusíková O; Tomová A
Neoplasma; 2003; 50(5):350-6. PubMed ID: 14628088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
